Pfizer Inc. (NYSE:PFE) Shares Bought by Huber Capital Management LLC

Huber Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 95,330 shares of the biopharmaceutical company’s stock after buying an additional 4,500 shares during the quarter. Huber Capital Management LLC’s holdings in Pfizer were worth $3,733,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. OLD Mission Capital LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at $291,000. Lehman & Derafelo Financial Resources LLC raised its holdings in shares of Pfizer by 3.6% in the 1st quarter. Lehman & Derafelo Financial Resources LLC now owns 212,511 shares of the biopharmaceutical company’s stock valued at $7,699,000 after purchasing an additional 7,354 shares in the last quarter. Ironwood Wealth Management LLC. raised its holdings in shares of Pfizer by 1.6% in the 1st quarter. Ironwood Wealth Management LLC. now owns 35,385 shares of the biopharmaceutical company’s stock valued at $1,282,000 after purchasing an additional 550 shares in the last quarter. Petix & Botte Co acquired a new stake in shares of Pfizer in the 1st quarter valued at $187,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Pfizer in the 1st quarter valued at $456,000. Institutional investors own 64.93% of the company’s stock.

In other news, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, July 30th. The shares were sold at an average price of $42.86, for a total transaction of $107,150.00. Following the completion of the transaction, the senior vice president now directly owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jennifer B. Damico sold 1,661 shares of the firm’s stock in a transaction that occurred on Friday, August 13th. The stock was sold at an average price of $48.30, for a total transaction of $80,226.30. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.

Several brokerages have recently issued reports on PFE. Truist initiated coverage on shares of Pfizer in a report on Tuesday, July 27th. They issued a “buy” rating and a $43.00 target price for the company. Royal Bank of Canada set a $44.00 price objective on shares of Pfizer in a research note on Thursday, July 29th. SVB Leerink upped their price objective on shares of Pfizer from $49.00 to $50.00 and gave the company a “market perform” rating in a research note on Monday, September 20th. Morgan Stanley upped their price objective on shares of Pfizer from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Tuesday. Finally, The Goldman Sachs Group set a $48.00 target price on shares of Pfizer in a research note on Thursday, July 29th. Ten investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $43.42.

NYSE PFE traded up $0.37 during trading hours on Thursday, hitting $41.79. 437,324 shares of the stock were exchanged, compared to its average volume of 30,215,465. The company has a market cap of $234.30 billion, a price-to-earnings ratio of 17.99, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74. Pfizer Inc. has a 12-month low of $33.36 and a 12-month high of $51.86. The stock has a 50-day moving average of $45.45 and a 200 day moving average of $41.51. The company has a quick ratio of 1.12, a current ratio of 1.37 and a debt-to-equity ratio of 0.50.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.97 by $0.10. The firm had revenue of $18.98 billion during the quarter, compared to analysts’ expectations of $17.54 billion. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. During the same period in the prior year, the company posted $0.78 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 4.12 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 6th. Shareholders of record on Friday, November 5th will be issued a $0.39 dividend. The ex-dividend date is Thursday, November 4th. This represents a $1.56 dividend on an annualized basis and a yield of 3.73%. Pfizer’s dividend payout ratio (DPR) is presently 70.27%.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More: Commodities

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.